טוען...
Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
BACKGROUND: Serious bleeding events have been frequently described in patients taking direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with bleeding outcomes. This study aimed to describe rivaroxaban plasma levels in patie...
שמור ב:
| הוצא לאור ב: | Thromb J |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6231259/ https://ncbi.nlm.nih.gov/pubmed/30455596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-018-0183-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|